Keymed Biosciences hits near 3-month high on product revenue growth

Keymed Biosciences

16/10/2026 03:28

    ** Shares of Keymed Biosciences  2162.HK  jump 12.5% to
HK$85.7, their highest level since July 24 
    ** Stock of biological therapies developer on course for 
biggest one-day pct rise since June 29 after three consecutive
sessions of falls
    ** Keymed recorded about 660 million yuan ($98.63 million) 
in revenue from product Kangyueda during the first three
quarters of 2026, up 227% y/y on support of national policies 
    ** Kangyueda is the trade name of IL-4Rα monoclonal antibody
stapokibart for treatment of inflammatory diseases 
    ** China's National Medical Products Administration has
approved marketing application for new indication of stapokibart
for treatment of atopic dermatitis in adolescents
    ** YTD, stock up 58.2%, Hang Seng Biotech Index  .HSBIO  up
6.47%
    ($1 = 6.6918 Chinese yuan)

    (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))